

CrossMark
click for updatesCite this: *Med. Chem. Commun.*, 2015,
6, 247

Correction: Design and chemoproteomic functional characterization of a chemical probe targeted to bromodomains of BET family proteins

Jiang Wu,^a Julia Shin,^b Cara M. M. Williams,^b Kieran F. Geoghegan,^a
Stephen W. Wright,^c David C. Limburg,^c Parag Sahasrabudhe,^a Paul D. Bonin,^e
Bruce A. Lefker^{*d} and Simeon J. Ramsey^b

DOI: 10.1039/c4md90044h

www.rsc.org/medchemcommCorrection for 'Design and chemoproteomic functional characterization of a chemical probe targeted to bromodomains of BET family proteins' by Jiang Wu *et al.*, *Med. Chem. Commun.*, 2014, 5, 1871–1878.

The following scheme captions were missing from the paper:

Scheme 1 (a) 2-ethyl-4,4-dimethyl-4,5-dihydroazole, NaHSO₄, NMP, xylenes, 200 °C, 93%; (b) 10% Pd/C, acetic acid, 84%; (c) 2-methoxybenzenesulfonyl chloride, pyridine, 46%.**Scheme 2** (a) acrylonitrile, NaOH, 26%; (b) Adam's catalyst, ethanol, CHCl₃, 99%; (c) di-*tert*-butyl dicarbonate, TEA, THF, 37%; (d) **6**, polymer bound TPP, DIAD, 79%; (e) benzyltrimethylammonium chloride, trichloroisocyanuric acid, H₂O, ACN, 92%; (f) **5**, pyridine, 68%; (g) TFA, CH₂Cl₂, 0–20 °C, 100%; (h) desthiobiotin, DMF, DIEA, HATU, 15%.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

^aStructural Biology and Biophysics, Worldwide Medicinal Chemistry, Pfizer, Groton, CT 06340, USA^bInflammation and Remodeling Research Unit, Pfizer, Cambridge, MA 02139, USA^cWorldwide Medicinal Chemistry, Pfizer, Groton, CT 06340, USA^dWorldwide Medicinal Chemistry, Pfizer, 610 Main Street, Cambridge, MA 02139, USA. E-mail: bruce.a.lefker@pfizer.com; Fax: +1 860-715-8059; Tel: +1 617-674-7450^ePrimary Pharmacology Group, Pfizer, Groton, CT 06340, USA